Attivare Therapeutics ← Back to Website

Scientific Presentations

AACR Annual Meeting 2025

American Association for Cancer Research  ·  April–May 2025  ·  Chicago, IL

ATT-01  ·  AML

Intratumoral ATTImmune Scaffold Delivering GM-CSF & CpG for Treatment of Acute Myeloid Leukemia

Preclinical data demonstrating the efficacy of ATT-01, Attivare's lead AML program, using the ATTImmune biomaterial scaffold for localized co-delivery of GM-CSF and CpG directly to the tumor microenvironment.

ATT-02  ·  Solid Tumors

Intratumoral ATTImmune Scaffold Delivering IL-12 Drives Abscopal Effects & Complete Response in Solid Tumors

Preclinical data for ATT-02 demonstrating robust tumor microenvironment modulation, abscopal (systemic) immune effects, and complete responses in solid tumor models using localized IL-12 delivery via ATTImmune.

ATT-01 Poster — AML

ATT-02 Poster — Solid Tumors